Vaccinex, Inc. Announces Intermin Response Data from KEYNOTE Study
Jan 26, 2022 By MarketDepth
Vaccinex, Inc. (Nasdaq: VCNX) reported its interim response data in the Phase Ib segment of the KEYNOTE-B84 study earlier today.
Results from Study
The KEYNOTE-B84 study of the Company’s pepinemab in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with recurrent or metastatic head and neck squamous cell carcinoma, enrolled three patients to assess the potential Dose Limiting Toxicity.
Good Response from Patients
Two out of the three patients were observed to experience a complete response and the trial’s Data Safety Monitoring Board determined that the recommended phase 2 dose of pepinemab, in combination with KEYTRUDA , appeared to be well-tolerated.
Trials have Begun Across USA
The KEYNOTE-B84 study will now enroll an additional 62 patients across 18 U.S. trial sites.
“Notably, pepinemab in combination with KEYTRUDA does not include administration of chemotherapy…We look forward to sharing further results at a medical conference as the study progresses, with interim analysis around the midpoint of enrollment,”
Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex
